Company profile
Protara Therapeutics, Inc.
NASDAQ: TARA · Healthcare · Biotechnology
#755 of 1,418 Healthcare companies by revenue41st-percentile growth
EA Score
43DFH 49DQ 30GM —SS 58
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ disclosure history, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$57.4M
Employees
46
as of 2026-08-14
Market cap
$221.4M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.9M$2.9M2014
Net income-$57.4M-$57.4M2025
Operating income-$64.5M-$64.5M2025
Total assets$209.5M$209.5M2025
Liabilities$13.1M$13.1M2025
Equity$196.4M$196.4M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Protara Therapeutics, Inc.’s revenue?
Protara Therapeutics, Inc. booked $2.9M in FY2014 revenue, growing 0.0% year over year — about the middle of the pack among Healthcare companies we track, at a -1948.4% net margin.
Peers · Healthcare
TherapeuticsMD, Inc.60CXenetic Biosciences, Inc.56CPeakBirch Commerce Inc.——OSR Holdings, Inc.34DAmexdrug Corporation69BRadient Technologies Inc.——Neighbors
New York →Key facts
CEOJesse Shefferman
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York City, NY
ExchangeNASDAQ: TARA
Employees46
IPO date2014-10-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.